QQ客服 官方微博 反馈留言

	Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
	Wu Bin[1]; Zhang Qiang[2]; Sun Jie[3]
刊名	Journal for immunotherapy of cancer
	2018
卷号	6页码:124
关键词	Cost-effectiveness Ipilimumab Nivolumab Renal cell carcinoma Sunitinib
ISSN号	2051-1426
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2170261
专题	上海大学
作者单位	1.[1]Medical Decision and Economic Group, Department of Pharmacy, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. 2.[2]Department of Clinical Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. 3.[3]Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. scilwsjtu-sunjie@yahoo.com.
推荐引用方式 GB/T 7714	Wu Bin[1],Zhang Qiang[2],Sun Jie[3]. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma[J]. Journal for immunotherapy of cancer,2018,6:124.
APA	Wu Bin[1],Zhang Qiang[2],&Sun Jie[3].(2018).Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.Journal for immunotherapy of cancer,6,124.
MLA	Wu Bin[1],et al."Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma".Journal for immunotherapy of cancer 6(2018):124.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。